Spero Therapeutics Investor Relations Material

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. Their proprietary platform technology utilizes small molecules to target specific bacterial populations that are a major source of infection in critically ill patients or those with immune deficiencies.